Agios Pharmaceuticals (AGIO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.69
- Estimate
- -$1.66
- Surprise
- -1.5%
- Revenue (period 2026-06-30)
- $44.7M
- Score today
- 4.7/10
Revenue source: xbrl.
How the report landed
Agios Pharmaceuticals (AGIO) reported a wider loss than forecast — adjusted EPS of -$1.69 against the -$1.66 estimate (a 1.5% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates AGIO Sell at 4.7/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -1.5% surprise compares with a +3.9% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Product: PYRUKYND® / AQVESME™
- Quality below floor (2.2 < 4.0)
- Reward/Risk 0.3:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $38.23
- Price target
- $39.91
- Stop
- $35.55
- Upside to target
- +4.4%
- Reward-to-risk
- 0.3:1
Risk check: RSI 76 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
AGIO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.28B
- P/E (fwd)
- -9.4
- 52-week range
- $22.24–$46.00
- Off 52-week high
- 16.9%
- RSI (14)
- 76
- Volume vs avg
- 0.06×
- Score today
- 4.7/10